Cognition Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Lowers Price Target to $5
Cognition Therapeutics Analyst Ratings
B.Riley Financial Downgrades Cognition Therapeutics(CGTX.US) to Hold Rating, Cuts Target Price to $1
Cognition Therapeutics Analyst Ratings
H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Cuts Target Price to $7
Ladenburg Thalmann Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Cuts Target Price to $5
Oppenheimer Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $9
Oppenheimer Reaffirms Their Buy Rating on Cognition Therapeutics (CGTX)
Cognition Therapeutics Analyst Ratings
Cantor Fitzgerald Downgrades Cognition Therapeutics(CGTX.US) to Hold Rating
Cognition Therapeutics Analyst Ratings
Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target
Cognition Therapeutics Analyst Ratings
Cognition Therapeutics Analyst Ratings
Buy Rating Affirmed for Cognition Therapeutics on Promising Alzheimer's Drug Candidate CT1812
Oppenheimer Sticks to Their Buy Rating for Cognition Therapeutics (CGTX)
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
Cognition Therapeutics Analyst Ratings
Buy Rating Affirmed for Cognition Therapeutics Amid Promising CT1812 Clinical Trials
No Data
No Data